Details

Autor(en) / Beteiligte

• Barlogie, Bart
• Tricot, Guido
• Anaissie, Elias
• Shaughnessy, John
• Rasmussen, Erik
• van Rhee, Frits
• Fassas, Athanasios
• Zangari, Maurizio
• Hollmig, Klaus
• Pineda-Roman, Mauricio
• Lee, Choon
• Talamo, Giampaolo
• Thertulien, Raymond
• Kiwan, Elias
• Krishna, Somashekar
• Fox, Michele
• Crowley, John

Titel

Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2006-03, Vol.354 (10), p.1021-1030

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized trial of the treatment of multiple myeloma with intensive chemotherapy plus autologous hematopoietic stem-cell support, the addition of thalidomide improved the rates of complete response and event-free survival, but not overall survival. In the treatment of multiple myeloma with intensive chemotherapy plus autologous hematopoietic stem-cell support, the addition of thalidomide improved the rates of complete response and event-free survival, but not overall survival. The steep dose–response effect of melphalan in patients with multiple myeloma can be used to therapeutic advantage when supported with infusions of autologous peripheral-blood stem cells. 1 , 2 After a pilot trial of two transplantations in patients with multiple myeloma, 3 a larger trial (the InterGroupe Francophone du Myélome) reported seven-year event-free and overall survival rates of 20 and 40 percent, respectively — twice the rates obtained with single transplantations. 4 , 5 Our phase 3 randomized trial was prompted by the demonstration of the efficacy of thalidomide (Kevadon) in multiple myeloma that is refractory to post-transplantation salvage therapies. 6 , 7 We sought to determine . . .